Search research articles
Contact Us
Filters
Showing results (411-420 of 471) with videos related to
Page
of 48
Sort By:
Gastrointestinal Endoscopy
|
November 19, 2022
Interobserver agreement of the modified Paris classification and histology prediction of colorectal lesions in patients with inflammatory bowel disease
Daniela Guerrero Vinsard, David H Bruining, James E East, et al.
The American Journal of Gastroenterology
|
January 22, 2014
Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography
Nicholas K Weber, Jeff L Fidler, Tony M Keaveny, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 1, 2014
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis
David S Kotlyar, James D Lewis, Laurent Beaugerie, et al.
Journal of Crohn'S & Colitis
|
November 20, 2025
Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Severine Vermeire, Jean-Frederic Colombel, Silvio Danese, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V Loftus, Jean-Frédéric Colombel, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
Remo Panaccione, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Crohn's Disease
Severine Vermeire, Edward V Loftus, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis
|
December 9, 2017
Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease
Amy L Lightner, Nicholas P McKenna, Chung Sang Tse, et al.
The New England Journal of Medicine
|
May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease
Edward V Loftus, Julian Panés, Ana P Lacerda, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Page
of 48
Search research articles
Search
Showing results (411-420 of 471) with videos related to
Sort By:
Page
of 48
Gastrointestinal Endoscopy
|
November 19, 2022
Interobserver agreement of the modified Paris classification and histology prediction of colorectal lesions in patients with inflammatory bowel disease
Daniela Guerrero Vinsard, David H Bruining, James E East, et al.
The American Journal of Gastroenterology
|
January 22, 2014
Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography
Nicholas K Weber, Jeff L Fidler, Tony M Keaveny, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 1, 2014
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis
David S Kotlyar, James D Lewis, Laurent Beaugerie, et al.
Journal of Crohn'S & Colitis
|
November 20, 2025
Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Severine Vermeire, Jean-Frederic Colombel, Silvio Danese, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V Loftus, Jean-Frédéric Colombel, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
November 27, 2023
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis
Remo Panaccione, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis
|
September 30, 2016
Long-term Efficacy of Vedolizumab for Crohn's Disease
Severine Vermeire, Edward V Loftus, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis
|
December 9, 2017
Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease
Amy L Lightner, Nicholas P McKenna, Chung Sang Tse, et al.
The New England Journal of Medicine
|
May 24, 2023
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease
Edward V Loftus, Julian Panés, Ana P Lacerda, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Page
of 48